|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
Biotechnology's innovation. Latest discover of recombinant human protein with procoagulant factors to stop bleeding, topically. The TT-103MH is being developed by Thrombotargets and will arrive at clinical phase at beginning of 2008.
New hemophiliac medication: TT-103MH. All the studies have confirmed that TT-103MH is projected like the only approach to treat topical bleeding episodes in hemophiliacs' patients, even when a lethal hemorrhage is present.
Know the TT-103MH haemostatic agent for all kind of bleeding treatments discovered by Thrombotargets, the biotech corporation that works to improve the quality of life for millions of people.
|
|
|
|
